邵锋,李良海.替加环素联合头孢哌酮舒巴坦治疗多重或泛耐药鲍曼不动杆菌感染的临床观察[J].内科急危重症杂志,2016,22(2):
扫码阅读全文
|
| DOI： |
| 中文关键词: 头孢哌酮舒巴坦 替加环素 多或泛耐药鲍曼不动杆菌 |
| 英文关键词:cefoperazone sulbactam tigecycline muiti or extensiveIy drug resistant Acinetobacter baumannii |
| 基金项目: |
|
| 摘要点击次数: 2614 |
| 全文下载次数: 3743 |
| 中文摘要: |
| 目的：观察替加环素联合头孢哌酮舒巴坦治疗临床多重或泛耐药鲍曼不动杆菌感染的临床疗效。方法：回顾性分析2013年1月至2014年6月我院重症医学科45例多重或泛耐药鲍曼不动杆菌感染患者使用替加环素联合头孢哌酮舒巴坦治疗的病例资料，观察患者治疗前后的炎症指标、临床疗效、细菌清除率、不良反应发生率及病死率。结果：患者感染的鲍曼不动杆菌均表现为多重或泛耐药性，联合用药后治疗的总有效率为55.5%，细菌清除率为71.4%，病死率为12.5%；炎症指标PCT、WBC和CRP的水平均明显低于治疗前，差异有统计学意义(P<0.05)。治疗后患者不良反应发生率为17.5%，主要表现为肝功能受损和胃肠道反应，且程度较轻。结论：针对多重或泛耐药鲍曼不动杆菌感染可尝试替加环素联合头孢哌酮舒巴坦联合治疗，但具体尚需进一步的临床证据 |
| 英文摘要: |
| Objective To observe the clinical effect of tigecycline associated with cefoperazone sulbactam for treatment of infection caused by muiti or extensively drug-resistant Acinetobacter baumannii. Methods 45 patients infected with muiti or extensiveIy drug-resistant Acinetobacter baumannii pneumonia were analyzed from January 2013 to June 2014. The level of PCT, CRP, WBC and clinical cure rates were collected and compared before and after treatment, as well as microbiological eradication, side effect and morality. Results Patients were infected with Acinetobacter baumannii, which was charactered with muiti or extensively drug resistant. After combined treatment, the clinical effective rate, the Bacterial clearance rate and the morality rate were 55.5%, 71.4% and 12.5%, respectively. Compared with before treatment, the level of PCT, WBC and CRP was significantly decreased (P<0.05). After combined treatment, the side effect rate was 17.5%，mainly characted as the?liver function damage?and?gastrointestinal tract?reaction,?and?to a lesser degree. Conclusion Tigecycline combined cefoperazone sulbactam can be tried for the treatment of multi-drug resistant or extensively drug resistant Acinetobacter baumannii infection, but the specific?still need?further?clinical?evidence. |
|
|
|
|
